acromegaly
ACROMEGALY
Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.

Surgical Intervention

  • Surgical intervention is the 1st-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure

Patients not Eligible for Surgical Treatment

  • Medically unstable condition
  • Patients with airway difficulties and are at high risk for anesthetic complications
  • Major systemic manifestations of acromegaly:
    • Cardiomyopathy
    • Severe hypertension
    • Uncontrolled diabetes mellitus

Goals of Surgical Treatment

  • To decrease tumor burden, and to cure if possible, with preservation of normal pituitary function
  • To reduce mass effect of macroadenomas on remaining normal pituitary gland tissues, the optic chiasm or nerves, and other surrounding structures
  • To rapidly lower or reduce growth hormone and insulin-like growth factor-1 levels, control or prevent progression of disease, and relieve associated comorbidities

Transsphenoidal Surgery

  • Treatment of choice for all patients with microadenomas and or all patients who have macroadenomas with associated mass effect eg causing visual impairment
    • In patients with macroadenomas without mass effects but low likelihood of surgical cure, surgical debulking may improve response to subsequent medical therapy
    • Primary medical therapy alone has also been advocated for those with macroadenomas not likely to be cured by surgery
  • Transnasal endoscopic procedures have shown improved patients satisfaction and shorter hospital stay compared with traditional sublabial procedures, without compromising surgical success
  • Some clinicians have found benefits with the use of somatostatin receptor ligands (SRL) prior to surgery
    • Some have claimed pretreatment with SRLs has improved normalization of growth hormone and insulin-like growth factor-1 after surgery and shortened the duration of hospital stay
Outcomes
  • Surgical cure rates are dependent on anatomy, extent and invasion of tumor and neurosurgeon expertise
  • Cure rates for intrasellar microadenomas and macroadenomas are high with an experienced neurosurgeon and facility
  • Control suggests GH levels <1 ng/mL (with IRMA or chemiluminescence assay after a 75-g oral glucose followed by GH measurements every 30 minutes for 120 minutes) and normalized age and gender matched IGF-1 levels and alleviation of tumor mass effects
  • Repeat surgery can be considered in patients with residual intrasellar disease following initial surgery and when the tumor is accessible
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.